Turck Dominique, Castenmiller Jacqueline, De Henauw Stefaan, Hirsch-Ernst Karen Ildico, Kearney John, Maciuk Alexandre, Mangelsdorf Inge, McArdle Harry J, Naska Androniki, Pelaez Carmen, Pentieva Kristina, Siani Alfonso, Thies Frank, Tsabouri Sophia, Vinceti Marco, Cubadda Francesco, Engel Karl-Heinz, Frenzel Thomas, Heinonen Marina, Marchelli Rosangela, Neuhäuser-Berthold Monika, Poulsen Morten, Sanz Yolanda, Schlatter Josef Rudolf, van Loveren Henk, Bernasconi Giovanni, Germini Andrea, Knutsen Helle Katrine
EFSA J. 2020 Jan 17;18(1):e05947. doi: 10.2903/j.efsa.2020.5947. eCollection 2020 Jan.
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the extension of use of calcium l-methylfolate to be used as a source of folate added for nutritional purposes to infant and follow-on formula, baby food and processed cereal-based food pursuant to Regulation (EU) 609/2013. In 2004, EFSA assessed the use of calcium l-methylfolate as a source of folate in foods for particular nutritional uses, food supplements and foods intended for the general population. The new alternative synthetic step proposed to produce the nutrient source, using platinum as a catalyst, did not raise any safety concern and the production process was found to consistently yield a product in line with the proposed specifications. Based on the studies assessed in the previous evaluation, it was concluded that calcium l-methylfolate is non-genotoxic and that subchronic and embryotoxicity/teratogenicity studies in rats did not reveal any adverse effects up to the highest doses tested. The Panel considered that no additional toxicological studies are required on the nutrient source. The intervention study in healthy infants provided by the applicant did not indicate differences in growth and tolerance parameters in infants who consumed either an infant formula supplemented with calcium l-methylfolate or with folic acid, and did not raise concerns regarding safety or tolerability of the infant formula with the proposed nutrient source. The study also provided further supporting evidence for the bioavailability of calcium l-methylfolate. The Panel considers that calcium l-methylfolate is a source from which folate is bioavailable and concludes that calcium l-methylfolate is safe under the proposed uses and use levels for infants and young children.
应欧盟委员会的要求,欧洲食品安全局(EFSA)营养、新型食品及食品过敏原专家小组(NDA)被要求就根据欧盟法规(EU)609/2013将L-甲基叶酸钙用作叶酸来源添加到婴儿配方奶粉、后续配方奶粉、婴儿食品和谷物类加工食品中以用于营养目的的使用范围扩展提供科学意见。2004年,EFSA评估了L-甲基叶酸钙作为叶酸来源在特殊营养用途食品、食品补充剂及普通人群食品中的使用情况。提议采用铂作为催化剂生产该营养素来源的新合成步骤未引发任何安全问题,且生产过程被认定能持续产出符合提议规格的产品。基于先前评估中所评估的研究,得出结论:L-甲基叶酸钙无遗传毒性,大鼠亚慢性及胚胎毒性/致畸性研究在最高测试剂量下均未显示出任何不良反应。专家小组认为无需对该营养素来源进行额外的毒理学研究。申请人提供的针对健康婴儿的干预研究表明,食用添加了L-甲基叶酸钙的婴儿配方奶粉或叶酸的婴儿在生长和耐受性参数方面没有差异,且未对含有提议营养素来源的婴儿配方奶粉的安全性或耐受性提出担忧。该研究还为L-甲基叶酸钙的生物利用度提供了进一步的支持证据。专家小组认为L-甲基叶酸钙是一种叶酸可生物利用的来源,并得出结论:在提议的婴幼儿使用用途和使用水平下,L-甲基叶酸钙是安全的。